Medipal Holdings Corporation · TSE:7459
Medipal — Q2 FY2025 Earnings Presentation
29 slides from Medipal's earnings presentation, Nov 5, 2025
Slide 1: Financial Results for the Second Quarter Ended September 30, 2025
November 5, 2025 Financial Results for the Second Quarter Ended September 30, 2025 Expand, Support, and Connect “Pharmaceuticals, Health, and Beauty” an Orchestra in Support of People's Health The MEDIPAL Group aims to realize a society in which everyone can live with physical and mental well-being
Slide 2: Contents
Contents Financial Results for the Second Quarter 1 Ended September 30, 2025 Initiatives for the Second Quarter 2 Ended September 30, 2025 3 Appendix The MEDIPAL Group has three business segments: Regarding the description of the business period ・ Prescription Pharmaceutical Wholesale Business (MEDI
Slide 3: Overview of Financial Results for 2Q/FY2025
Overview of Financial Results for 2Q/FY2025 MEDICEO and PALTAC businesses performed well, and made strategic investments essential for future growth Performance progressed as expected in the full-year forecast. In line with the 2027 Medium-Term Vision, we will continue to promote our future-oriented
Slide 4: 2Q/FY2025 Consolidated Results
2Q/FY2025 Consolidated Results Net Sales increased in all business segments. Adjusted operating profit, excluding the impact of business investment expenses, etc., increased Profit Attributable to Owners of Parent increased Amount YoY Change Change factors from 2Q/2024 Net Sales ¥1,897.5 billion ＋¥7
Slide 5: 2Q/FY2025 MEDICEO Business
2Q/FY2025 MEDICEO Business Our initiatives, “the two A‘s (ALC and AR*)”, enabled us to secure sales exceed market growth Increased both gross profit and adjusted operating profit Amount YoY Change Change factors from 2Q/2024 • Prescription Pharmaceutical sales outpaced market growth Sales expansio
Slide 6: 2Q/FY2025 PALTAC Business
2Q/FY2025 PALTAC Business Both Sales and Gross profit increased. SG&A expenses also increased due to investment in personnel, etc. ・Increased sales due to successful acquisition of accounts and expansion of new merchandise. ・Gross profit increased, but SG＆A expenses increased, resulting in flat oper
Slide 7: 2Q/FY2025 AGRO&FOOD Business
2Q/FY2025 AGRO&FOOD Business Gross profit increased due to steady sales and revised sales prices, and absorbed rising costs due to the weak yen Strengthening strategic investments in HR, systems, and R&D for future growth. Amount YoY Change Change factors from 2Q/FY2024 Animal Health Products whol
Slide 8: Forecast of Consolidated Results for the FY2025
Forecast of Consolidated Results for the FY2025 Progressing in line with the full-year forecast Forecast of Consolidated Results （¥ billion) 2Q/FY2025 Consolidated Results for the FY2025 [% of [% of Progress rate YoY YoY (Against full-year Net Sales] Net Sales] forecast) Net Sales 3,785.0 +3.1% 1,89
Slide 9: Initiatives for the Second Quarter
Contents Financial Results for the Second Quarter 1 Ended September 30, 2025 Initiatives for the Second Quarter 2 Ended September 30, 2025 3 Appendix Copyright © 2025 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 8
Slide 10: Initiatives for the 2Q/FY2025
Initiatives for the 2Q/FY2025 Actively promoting initiatives in line with the growth strategies of the "2027 MEDIPAL Medium-Term Vision" Sustainable grow th ～Constant Innovation～ of MEDIPAL group (Creating Social and Customer Value) Five growth strategies Method for implementing the strategies Busin
Slide 11: MEDICEO Business Initiatives for the Growth Strategies
MEDICEO Business Initiatives for the Growth Strategies 【Building sustainable logistics business/Value co-creation in community healthcare】 Our initiatives, “the two A’s(ALC＆AR)" , enable us to meet the expectations of both manufacturers and customers Expectations Expectations trust trust Pharmaceuti
Slide 12: Initiatives for the Growth Strategies: Building sustainable logistics business
MEDICEO Business Initiatives for the Growth Strategies 【Building sustainable logistics business】 Our logistics structural reform enables us to accept outsourced logistics from other companies and improve efficiency within the Group A chronic labor shortage and intensifying competition for personne
Slide 13: Growth Strategy: Expansion of Overseas Business
MEDICEO Business Growth Strategy 【Expansion of Overseas Business】 Acquired commercialization rights for a new therapeutic drug candidate (JR-479) from JCR Pharmaceuticals Co., Ltd. Strengthening the development pipeline for ultra-orphan drugs Month/Year of contract signing Code Indication Country/re
Slide 14: PALTAC Business Initiatives for the Growth Strategies
PALTAC Business Initiatives for the Growth Strategies 【Building sustainable logistics business】 "Challenge toward New Value Creation" in the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business Capital and business alliance with FEZ Inc. Promoting digital transformation through s
Slide 15: AGRO&FOOD Business: Expansion of AGRO&FOOD business
AGRO・FOOD Business Initiatives for the Growth Strategies 【Expansion of AGRO&FOOD business】 * MP AGRO plans to acquire Cygni Corporation, a company with strengths in the EC(e-commerce) business Establishing a dominant position in the companion animal market and creates further growth opportunities Ac
Slide 16: AGRO&FOOD Business: MP Gokyo Food & Chemical
AGRO・FOOD Business Initiatives for the Growth Strategies 【Expansion of AGRO&FOOD business】 MP Gokyo Food & Chemical Co., Ltd. will strengthen its profitability by focusing on the future growth drivers of "overseas expansion of polysaccharides" and "strengthening of the electronic pharmaceutical busi
Slide 17: Sustainability Activities
Sustainability Activities Promoting decarbonization and initiatives for diversity and inclusion Continuing to work towards achieving our goals to contribute to a sustainable society and improve our corporate value Targets for FY2030 Greenhouse Gas Emissions Percentage of Female Employees Percentage
Slide 18: Financial Activities
Financial Activities Allocating cash toward growth investments outlined in the MEDIPAL Medium-Term Vision, capital investments to build a robust distribution system, and shareholder returns. Acquisition and cancellation of treasury stock Sales of strategic investment shares → Conducted share buy
Slide 19: 2027 MEDIPAL Medium-Term Vision
2027 MEDIPAL Medium-Term Vision Growing through business portfolio prioritizations and collaboration with partners Oroshi Change the 卸 Forever 〜Constant Innovation〜 FY2022 〜 FY2024 FY2025 FY2026 ～ Examined and implemented strategic Implemented a future-oriented Achieving sustainable growth investmen
Slide 20: Appendix
Contents Financial Results for the Second Quarter 1 Ended September 30, 2025 Initiatives for the Second Quarter 2 Ended September 30, 2025 3 Appendix Copyright © 2025 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 19
Slide 21: 2Q/FY2025 Consolidated Statements
2Q/FY2025 Consolidated Statements （¥ billion) 2Q/FY2024 2Q/FY2025 Results Results YoY [% of Net Sales] [% of Net Sales] YoY Change % of Change Net Sales 1,824.6 1,897.5 +72.8 +4.0% Gross Profit 126.4 130.2 +3.8 +3.0% [6.93％] [6.87％] [(0.06pp)] 99.2 105.1 +5.9 +6.0% SG&A Expenses [5.44%] [5.54％] [+0.
Slide 22: Factors behind YoY changes in Gross Profit, Operating Profit, and Ordinary Profit
Factors behind YoY changes in Gross Profit, Operating Profit, and Ordinary Profit （¥ billion) +1.4 SG＆A expenses（Increase） Non-Operating Income/Expenses Profit from (5.9) MEDICEO +1.2 +2.3 Profit from Business PALTAC investment costs +3.8 (3.0) SG＆A expenses of MEDICEO, etc. SG＆A expenses Profit of
Slide 23: Factors behind YoY changes in Ordinary Profit, Profit before Income Taxes, and Profit
Factors behind YoY changes in Ordinary Profit ,Profit before Income Taxes, and Profit attributable to Owners of Parent （¥ billion) Extraordinary Income/Expenses +0.8 Gain on sale Business restructuring of investment expenses related to securities logistics operations +5.0 （4.2） Profit attributable I
Slide 24: 2Q/FY2025 MEDICEO Business
2Q/FY2025 MEDICEO Business (¥ billion) 2Q/FY2024 2Q/FY2025 Results Results YoY （% of Net Sales） （% of Net Sales） YoY Change % of Change Net Sales 1,167.6 1,215.7 +48.1 +4.1% Gross Profit 74.1 75.5 +1.4 +1.9% [6.35%] [6.22%] [(0.13pp)] SG&A Expenses 62.2 65.8 +3.6 +5.8% [5.33%] [5.42%] [+0.09pp] SG&A
Slide 25: 2Q/FY2025 PALTAC Business
2Q/FY2025 PALTAC Business (¥ billion) 2Q/FY2024 2Q/FY2025 Results Results YoY （% of Net Sales） （% of Net Sales） YoY Change % of Change Net Sales 600.4 625.1 +24.7 +4.1% 44.1 46.5 +2.3 Gross Profit +5.3% [7.36%] [7.44%] [+0.09pp] SG&A 30.2 32.6 +2.4 +8.1% Expenses [5.03%] [5.22%] [+0.19pp] Operating
Slide 26: 2Q/FY2025 AGRO&FOOD Business
2Q/FY2025 AGRO&FOOD Business (¥ billion) 2Q/FY2024 2Q/FY2025 Results Results YoY （% of Net Sales） （% of Net Sales） YoY Change % of Change Net Sales 58.6 58.6 +0.0 +0.0％ Gross Profit 8.1 8.2 +0.0 +0.6% [13.93%] [14.01%] [+0.08pp] SG&A Expenses 6.9 6.8 (0.1) (1.9%) [11.94%] [11.70%] [(0.23pp)] SG&A Ex
Slide 27: Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows （¥ billion) ＋５.2 (１5.9) ＋２５.5 Cash Flows from Investing Activities 274.1 • Proceeds from sale and Cash Flows from redemption of investment Financing Activities 259.3 • securities：+12.7 Purchase of property, plant and equipment：(4.7) • Purchase of treasury Cash F
Slide 28: Management Philosophy
Management Philosophy Contributing to people’s health and the advancement of society through creation of value in distribution Copyright © 2025 MEDIPAL HOLDINGS CORPORATION, All rights reserved. 27
Slide 29: Forward-Looking Statements
【Forward-Looking Statements】 These materials reflect analysis of available information and various trends as of the date on the cover. Risks and uncertainties affecting the Company’s business could cause actual results to differ materially from any projections presented in these materials. In the ev